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Abstract 
At present, there are no compounds in clin-
ical  development  in  the  field  of  chronic
myeloid leukemia (CML) or Philadelphia-posi-
tive (Ph
+) acute lymphoblastic leukemia (ALL)
that have been documented to harbor signifi-
cant  activity  against  the  imatinib-resistant
T315I  mutation.  Recent  reports  on  the  pre-
clinical  activity  of  some  emerging  tyrosine
kinase inhibitors such as ON012380, VX-680
and PHA-739358 promise possible clinical effi-
cacy against this specific Bcr-Abl mutant form.
Here, we focus on the role of aurora kinase
inhibitor VX-680 and PHA-739358 in blocking
the  leukemogenic  pathways  driven  by  wild-
type and T315I-Bcr-Abl in CML or Ph
+ ALL by
reviewing recent research evidence. We also
discuss  the  possibility  of  employing  aurora
kinase inhibitors as a promising new thera-
peutic approach in the treatment of CML and
Ph
+ ALL patients resistant to first and second
generation TK inhibitors.  
Introduction
The molecular signature of chronic myeloid
leukemia  (CML)  and  Philadelphia-positive
(Ph
+) acute lymphoblastic leukemia (ALL) is
the Bcr-Abl hybrid gene, originating from a
reciprocal t(9;22) chromosomal translocation
on the 22q- derivative, commonly referred to
as the Philadelphia chromosome.
1 The result-
ing fusion protein, Bcr-Abl, displays deregu-
lated tyrosine kinase activity and drives CML.
2
The disease begins with an indolent chronic
phase  (CP)  marked  by  the  expansion  of
myeloid cells with normal differentiation, and
then inexorably proceeds to advanced phases,
i.e., accelerated phase (AP) and the terminal
blastic phase (BP). Imatinib (Gleevec, Glivec;
STI571), a relatively selective tyrosine kinase
inhibitor that blocks the catalytic activity of
Bcr-Abl, is now the first-line treatment for all
newly diagnosed CML patients. Despite excel-
lent clinical results, there is still a need to
improve therapy for patients with CML and
Ph
+ ALL. More than 80% of newly diagnosed
CML  patients  treated  with  imatinib  in  CP
achieve a complete cytogenetic remission, as
typified  by  the  absence  of  the  Philadelphia
chromosome at the examination of 20 bone
marrow meta-phases.
3 However, residual Bcr-
Abl transcripts persist in the majority of these
patients, as assessed by sensitive assays such
as  nested  reverse  transcription-polymerase
chain  reaction,  and  represent  the  potential
pool from which disease recurrence may orig-
inate. While responses in CML in CP patients
have been shown to last more than five years,
3
most responding patients with AP- and BP-
CML, as well as those with Ph
+ ALL, relapse
early despite continued therapy. Resistance to
imatinib is most commonly mediated by Abl
kinase  domain  mutations.
4 We  and  other
authors have reported that approximately half
CML patients have evidence of point muta-
tions  within  the  Abl  kinase  domain  at  the
time of resistance to imatinib. Mutations tar-
get critical contact points between imatinib
and Bcr-Abl or, more often, induce a confor-
mation to which imatinib is unable to bind.
5
In  the  remaining  patients,  the  reasons  for
imatinib resistance have to be traced to Bcr-
Abl  gene  amplification  or  overexpression,
clonal cytogenetic evolution, or altered levels
of  transport  molecules  responsible  for  ima-
tinib  influx  and  efflux  (ABC  transporters,
hOCT1).
4
Abl  mutations  are  at  present  the  most
extensively investigated and best character-
ized mechanism of resistance to imatinib. So
far, at least 90 different point mutations have
been isolated from relapsed CML patients who
are resistant to imatinib.
6-7 The clinical and
pathogenetic  impact  of  mutations  varies
according to their different degree of residual
sensitivity to imatinib. Indeed, while certain
Bcr-Abl mutations retain in vitro sensitivity to
imatinib  at  physiologically  relevant  concen-
trations and therefore may not be clinically
meaningful, others require increased doses of
imatinib, and some confer a highly resistant
phenotype (Table 1).
9
The T315I mutation is highly
resistant to imatinib
An  amino  acid  substitution  occurring  at
the  so-called  “gatekeeper”  residue,  i.e. 
threonine 315, has attracted particular inter-
est since it confers a high level of resistance
not only to imatinib therapy but also to all of
the  newly  developed  tyrosine  kinase
inhibitors entered in clinical trials. Co-crystal
structure analysis indicates that, on binding,
the hydroxyl group of threonine 315 forms a
crucial  hydrogen  bond  with  imatinib.
10
Moreover, the side chain of threonine also
sterically controls the binding of the inhibitor
to hydrophobic regions adjacent to the ATP-
binding site.
11 In 10-15% of imatinib-resistant
patients, especially those in more advanced
phases of disease, a threonine to isoleucine
amino  acid  substitution  may  be  observed.
The  T315I  abrogates  imatinib  binding
because  it  disrupts  the  above  mentioned
hydrogen  bond  and  introduces  a  bulkier
isoleucine  side  chain  into  the  gatekeeper
position.
12 However,  this  explanation  is  not
the  most  up-to-date.  In  fact,  as  recently
demonstrated, the T315I resistance to ima-
tinib mainly results from the breakdown of
interactions between imatinib and both E286
and M290.
13 As a result, biochemical and cel-
lular IC50 values of imatinib for the T315I-Bcr-
Abl have been shown to be >6400 times high-
er than those of wild-type Bcr-Abl (Table 1).
9
Some authors have suggested that the T315I
is associated with highly aggressive disease
phenotype  and  poor  outcome  if  no  timely
therapeutic  reassessment  is  made.
14,15
However, the effects of the T315I mutation on
kinase activity in vitro and transforming effi-
ciency of Bcr-Abl in vitro and in vivo have
been  very  recently  investigated,  suggesting
that in the absence of imatinib, there is nei-
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ther increased kinase activity nor any growth
advantage for cells carrying T315I-Bcr-Abl as
compared to wild-type Bcr-Abl.
5
The two second-generation
inhibitors in clinical 
development, dasatinib and
nilotinib, are ineffective
against the T315I mutant
To counteract the problem of resistance due
to point mutations, several second-generation
inhibitors have been synthesized and tested
in pre-clinical assays: nilotinib (AMN107),
8,16-18
dasatinib  (BMS-354825),
8,19-23 bosutinib,
24 VX-
680,
21,25 AP23464,
26,27 bafetinib,
28,29 PD166326,
PD180970  and  PD173955,
10,30-32 and
ON012380.
33 Two of them are currently being
evaluated in phase II clinical trials – the dual-
specificity Src/Abl inhibitor dasatinib and the
imatinib  derivative  nilotinib.  Dasatinib  is  a
novel, dual Src and Abl inhibitor entered in
clinical trials. It has been shown to be ~300
times  more  potent  than  imatinib  in  Bcr-Abl
inhibition assays. Excellent results in terms of
hematologic and cytogenetic response in CML
and  Ph
+ ALL  patients  resistant  to  imatinib
have been reported after dasatinib adminis-
tration.
34 Pre-clinical studies have demonstrat-
ed  that  dasatinib  is  active  against  at  least
fourteen  imatinib-resistant  Bcr-Abl  mutants
(M244V, G250E, Q252H/R, Y253F/H, E255K/V,
F317L, M351T, E355G, F359V, H396R, F486S).
19
The  only  imatinib-resistant  Bcr-Abl  isoform
that was clearly insensitive to dasatinib was
the  T315I  mutant,  which  retained  kinase
activity even in the presence of micromolar
concentrations of the compound (Table 1).
19
Accordingly,  imatinib-resistant  patients  har-
boring the T315I mutation have been shown
not  to  benefit  from  dasatinib  in  the  recent
phase I trial.
34
Nilotinib is a close relative of imatinib with
more than 20-fold improved affinity for wild-
type  Bcr-Abl.
16 It  is  highly  efficacious  in
patients with imatinib-resistant Ph
+ CML. In
vitro experiment with cell lines transformed
with mutated forms of Bcr-Abl showed IC50 pro-
liferation inhibition for most mutations with
the  exception  of  the  T315I,  which  remains
refractory to nilotinib
8 (Table 1). Accordingly,
clinical  responses  have  been  observed  in
patients with various imatinib-resistant Bcr-
Abl mutations but not in patients positive for
the T315I in the recent phase I trial.
35
Despite the pressing need for a clinically
effective T315I-Bcr-Abl inhibitor, relatively few
pre-clinical candidates have been reported. A
potential  pitfall  might  be  the  tendency  to
screen  initially  for  Abl  kinase  inhibition
rather  than  for  T315I-specific  inhibition.  A
promising  approach  is  to  design  inhibitors
targeting other regions of Bcr-Abl. For exam-
ple, ON012380, a putative substrate-competi-
tive inhibitor, exhibited low nanomolar activi-
ty against imatinib-resistant Bcr-Abl mutants,
including the T315I, in biochemical and cellu-
lar assays.
33
Aurora kinases as targets for
cancer
Between  these  new  promising  drugs,  VX-
680 and PHA-739358, two aurora kinase A, B
and  C  inhibitors,  have  a  leading  place.  The
aurora  kinases  are  a  family  of  serine/threo-
nine kinases involved in many cellular func-
tions, including progression through mitosis,
by regulating spindle formation, chromosome
segregation  and  cytokinesis.
35-37 The  overex-
pression of aurora kinases has been reported
in  many  human  solid  tumors,  leading  to
defects in centrosome function, aberrant spin-
dle assembly, misalignment of chromosomes,
abnormal cytokinesis and genetic instability,
determining the activation of oncogenic path-
ways.
38-40 Many  authors  reported  an  aberrant
expression of the aurora A and B kinases also
in leukemia cells, suggesting a potential role of
these  molecular  targets  in  the  treatment  of
CML  and  ALL.
41-42 Aurora  kinase  function  is
mediated  by  the  phosphorylation  of  several
substrates  that  have  important  roles  in  cell
division,  such  as  proteins  survivin,  CENP-A
and  serine  10  on  histone  H3.
37 The  aurora
kinases range in size from 309 to 403 amino
acids. They have a C terminal domain that is
Review
Table 1. Comparison between imatinib, dasatinib and nilotinib IC50 values obtained in Ba/F3 cellular proliferation assays. Adapted from [8].
Cellular proliferation
Abl variant Imatinib Nilotinib Dasatinib
IC50 (nM) Fold-change IC50 (nM) Fold-change IC50 (nM) fold-change
Wild-type 260 1 13 1 0.8 1
M244V 2,000 8 38 3 1.3 2
G250E 1,350 5 48 4 1.8 2
Q252H 1,325 5 70 5 3.4 4
Y253F 3,475 13 125 10 1.4 2
Y253H >6,400 >25 450 35 1.3 2
E255K 5,200 20 200 15 5.6 7
E255V >6,400 >25 430 33 11 14
F311L 480 2 23 2 1.3 2
T315I >6,400 >25 >2000 >154 >200 >250
F317L 1,050 4 50 4 7.4 9
M351T 880 3 15 1.2 1.1 1.4
F359V 1,825 7 175 13 2.2 3
L387M 1,000 4 49 42 3
H396P 850 3 41 3 0.6 0.8
H396R 1,750 7 41 3 1.3 2[Hematology Reviews 2009; 1:e1] [page 3]
responsible for regulation of the protein levels
via  proteasomal  degradation;  a  highly  con-
served catalytic domain; and a short N-termi-
nal domain that varies in length between the
kinases and contributes to the differing loca-
tions of the kinases within cells.
43 (Figure 1).
The aurora A isotype (also known as aurora,
Aurora-2, AIK, AIR-1, AIRK1, AYK1, BTAK, Eg2,
MmIAK1 and STK15) is widely expressed in
proliferating normal tissues, with expression
being cell-cycle-dependent and peaking at the
G2/M point of the cell cycle. During mitosis,
the kinase is virtually confined to the spindle
poles, where it is needed for centrosome sepa-
ration and maturation.
44 An overexpression of
aurora  A  causes  an  increase  in  centrosome
numbers and aneuploidy,
45leading to the trans-
formation of mammalian cells and also causes
resistance  to  apoptosis  induced  by  taxol  in
human cancer cell lines. Moreover, this kinase
is a key regulatory component of the p53 path-
way as its overexpression leads to increased
p53 degradation, which facilitates oncogenic
transformation.
46 Human  aurora  A  has  been
proposed  as  a  “drugable”  target  in  several
tumors  including  pancreatic,
46,47 hepatocellu-
lar,
48 breast,
49 nonendometriod,
50 and  ovarian
carcinomas,
51 gliomas
52 and  aggressive  non-
Hodgkin’s lymphoma.
53 Aurora B (also known
as Aurora-1, AIM-1, AIK2, AIR-2, AIRK-2, ARK2,
IAL-1 and STK12) activity is required for bipo-
lar  chromosome  orientation  and  condensa-
tion.
54 Aurora B kinases are chromosomal pas-
senger proteins, which are found in cells in a
complex  with  inner  centromere  protein
(INCENP) and survivin. The overexpression of
an aurora B kinase-dead mutant (K-R) causes
multiple  defects  in  the  mitotic  machinery,
including the loss of kinetochore attachment
to  microtubules  and  the  exit  from  mitosis
without  anaphase  or  cytokinesis.
55 Increased
Aurora B expression correlates with increased
grade in glioma and colon cancer
56-57 and with
anaplasia  in  thyroid  carcinoma.
58 Aurora  C
(also known as AIK3) expression plays a role
in  spermatogenesis  at  the  time  when  cells
assemble the two meiotic spindles and also co-
operates  with  aurora  B  to  regulate  mitotic
chromosome dynamics in mammalian cells.
59
Aurora C overexpression has been detected in
tumor cell lines in vitro
60and in biopsy samples
from colorectal carcinoma.
61
Novel aurora kinase inhibitors
effective against the T315I-
Bcr-Abl
Several compounds have been pre-clinically
screened for their inhibitory activity against
aurora  kinases  (VX680,  MLN8054,  AZD1152,
R766, R763, PHA-739358, AT9283) and many of
Review
Figure 1. Schematic representation of domain organization of aurora kinases. Aurora
kinases have three domains: the N-terminal and C-terminal domains which contain most
of the aurora’s regulatory motifs and the catalytic domain in the central region. The align-
ment of auroras A and B allows the identification of one distantly conserved ‘KEN’ motif,
spanning 11-18 residues. The ‘KEN’ motif acts as a Cdh
– dependant anaphase-promoting
complex recognition signal. 
COOH Aurora A
KEN motif
D-box activating motif
H2N
H2N
H2N
1 51 131 383 402
1 76 251 343
18 249 75
COOH Aurora B
COOH Aurora C
Table 2. Novel compound aurora-kinase inhibitors in clinical trial development.
TK inhibitor Company Phase Target(s)
MK-0457 Merck I-II Aurora, FLT-3, JAK-2
PHA-739358 Nerviano II Aurora
KW-2449 Kyowa I Aurora
Deciphera Decifera I Abl
AS703569 Merck Serono I-II Aurora, Abl, JAK-2
AZD1152 Astra-Zeneca I-II Aurora
Table 3. Comparison between the binding affinity of imatinib and of the aurora kinase
inhibitors BIRB-796 and MK-0457 for wild-type and drug-resistant Abl variants.
Adapted from [21]. Kd, nanomolar
Abl variant Imatinib BIRB-796 MK-0457
Wild-type 2 2,000 20
Q252H 20 4,000 10
Y253F 40 2,000 20
E255K 100 >10,000 50
M351T 10 2,000 8
F359V 20 8,000 20
T315I 6,000 40 5
H396P 60 >10,000 7
Table 4. Comparison between the binding affinity of imatinib and of the aurora kinase
inhibitors PHA-739358 and MK-0457 for wild-type and drug-resistant Abl variants. 
Adapted from [63].
WT E255V T315I M351T
(P loop)
Imatinib 0.230 0.610 >20.000 0.100
PHA-739358 0.021 0.014 0.005 0.015
MK-0457 0.083 0.205 0.085 0.045[page 4] [Hematology Reviews 2009; 1:e1]
them are being tested in clinical phase I/II tri-
als (Table 2). MK-0457 (VX-680) is a pan-auro-
ra kinase inhibitor with demonstrated in vitro
activity against wild-type and mutated Bcr-Abl,
including the T315I form, as well as FLT3 and
JAK-2.
21 Fascinatingly, Carter et al. have found
that  the  aurora  kinase  inhibitor  VX-680,
already in phase I trials, and the p38 inhibitor
BIRB-796,  in  clinical  trials  for  inflammatory
disease, inhibit the imatinib- and dasatinib-
resistant  T315I-Bcr-Abl  with  high  affinity
(Tables 3 and 4). In fact, contrasting results
related to this compound have been published.
In particular, BIRB-796 binds with good affini-
ty to T315I-Bcr-Abl (Kd = 40 nM), but has sig-
nificantly  weaker  affinity  for  wild-type  and
other imatinib-resistant forms of Abl, with Kd
values  >1  ʼM.
21 In  contrast,  as  reported  by
other authors, the compound fails to inhibit
the proliferation of cells expressing T315I, sug-
gesting a lack of clinical benefit for patients
harboring such a mutation.
22
In a recent phase I-II study, MK-0457 was
shown to be active in patients with T315I phe-
notype-refractory CML or Ph-positive ALL, with
no  significant  extramedullary  toxicity.
62
Because  of  a  potential  heart  safety  issue
revealed in one patient who experienced QTc
prolongation, the enrolment on phase II proto-
col  was  halted  in  November  2007.  Further-
more, an innovative phase I clinical study of
sequential  and  concomitant  treatment  with
dasatinib and MK-0457 has been conducted,
based on the suggestion that such a combina-
tory approach would suppress the emergence
of T315I and other resistant clones, improving
upon the response rate for dasatinib and the
durability of response. To date, 3 patients with
wild-type chronic myeloid leukemia (CML) or
Ph-positive  acute  lymphoblastic  leukemia
(ALL) have been enrolled, and this innovative
therapeutic  combination  showed  a  relevant
hematologic activity and a good safety profile.
PHA-739358 is a small molecule that selective-
ly inhibits the ATP site of Aurora-A (IC50=13
nM)  and  Aurora-B  (IC50=79  nM)  kinases.
63
Starting from the rationale that aurora kinases
play an important role in mitosis and that the
interruption of their function has significant
potential in the treatment of cancer, the drug,
formulated for intravenous infusion, is being
developed for therapeutic use in solid tumors
and  in  patients  with  Philadelphia  positive
leukemias.  Interestingly,  PHA-739358,  when
tested against a panel of more than 30 kinas-
es, has shown a strong cross-reactivity with c-
Abl (IC50=25 nM). Its inhibitory activity on ABL
in cells was confirmed in K562 leukemia cells
which  bear  the  Philadelphia  chromosome
related  translocation  Bcr-Abl.  Furthermore
PHA-739358  inhibits  phosphorylation  of
Tyr412, which is located in the kinase activa-
tion loop of Abl and is also active against the
T315I  mutant  of  Abl,  which  is  resistant  to
other ATP competitive inhibitors in the clinic,
such  as  gleevec,  and  second  generation  TK
inhibitors.  A  multicentric  phase  I/II  study,
aimed  to  test  PHA-739358  in  patients  with
chronic,  accelerated  or  blast  phase  CML
relapsing  on  gleevec  or  c-Abl  therapy  and
preferably  with  T315I  mutation  in  Bcr-Abl
kinase is ongoing. 
Binding mode of VX-680 and
PHA-739358 to Abl
The compound VX-680, developed by Vertex
Pharmaceuticals as an inhibitor of the aurora
kinases,  is  a  Y-shaped  molecule,  with  a 
N-methyl-piperazine group forming the base
or leg of the “Y”, a pyrimidine group at the
fork, and a methylpyrazole group at one arm
and a substituted phenyl group at the other
Review
Figure 2. Chemical structure of VX-680 aurora kinase inhibitor. [Reprinted and adapted
with permission from http://kinasepro.wordpress.com].
methylpyrazole 
pyrimidine
N-methylpiperazine 
VX-680 
(cyclopropane carboxylic acid {4-[4-(4-methyl-piperazin-1-
y1)-pyrimidin-2ylsulphanyl]-phenyl}-amide
phenyl 
cyclopropyl 
N
N N
N
HN N
H H
N N
S
O
Thr 315 - gatekeeper Thr 315 - gatekeeper
DFG motif
His 396
Abl: Imatinib Abl: VX-680
Pro 396
DFG motif
Figure 3. Structure of Abl domain kinase bound to imatinib (left) and to VX-680 (right).
[Reprinted and adapted with permission of AACR from: Young MA, et al. Structure of
the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora
kinase inhibitor VX-680. Cancer Res 2006 Jan 15;66(2):1007-14].arm (Figure 2). A recent study
25 showed that
VX-680 forms a hydrogen bond with the strict-
ly conserved Asp381 of the Asp-Phe-Gly (DFG)
motif in the Abl kinase domain and maintains
it in an orientation close to one that is normal-
ly seen in active kinases, although the activa-
tion loop of Abl is not phosphorylated in this
structure  (Figure  3).  Furthermore,  VX-680
does  not  deeply  penetrate  into  the  kinase
domain as imatinib does and it is anchored to
it by four hydrogen bonds. Three of these are
formed between two carbonyl groups (Glu316
and Met318) and an amide nitrogen (Met318)
in the “hinge region” of the kinase and three
nitrogen atoms, one in the linker between the
pyrimidine  group  and  the  methylpyrazole
group, and the other two in the methylpyrazole
group. These bonds are a common feature of
kinase inhibitors and are independent of the
sequence of the kinase.
59 Likewise, the fourth
hydrogen bond, made by VX-680 to the side
chain of Asp381 of the DFG motif, is to a strict-
ly invariant catalytic residue. Using these four
anchors, the inhibitor makes contact with 14
side chains within the kinase domain, eight of
which are identical between Abl and aurora.
One of the non-conservative substitutions is
at the gatekeeper position, where Thr315 in
Bcr-Abl  is  replaced  by  Leu210  in  aurora  A
kinase  (Figure  4).  The  side  chains  of
isoleucine  (at  position  315  of  Bcr-Abl)  and
leucine (at position 210 of aurora A kinase)
can be accommodated readily between the two
sides of the “Y” of VX-680. For this reason, VX-
680, in contrast to imatinib, is able to inhibit
the kinase activity of both wild-type Bcr-Abl
and T315I-Bcr-Abl. To understand the structur-
al  basis  of  the  capability  of  PHA-739358  to
bind and inhibit the T315I mutant, the crystal
structure of the inhibitor-protein complex was
determined
63 (Figure 5). The protein is in the
typical  conformation  of  active  kinases,  with
the activation loop in the extended DFG ‘‘in’’
conformation. Indeed, Asp381 points into the
active  site  and  interacts  with  Mg
2+ ion  that
occupies a position similar to the one usually
seen in the structures of kinases in complex
with ATP. The glycine loop adopts an extended
conformation, in contrast to the other publicly
available  Abl  structures  where  the  loop  is
more distorted, which could be due to the spe-
cific binding mode of our inhibitor. The puri-
fied T315I Abl kinase domain used for crystal-
lization experiments is predominantly phos-
phorylated  on  the  activation  loop  at  Tyr393,
whereas Tyr253, Tyr257, and Tyr264 are phos-
phorylated at lower levels. These interactions
probably stabilize the active conformation of
the  activation  loop,  which  is,  however,  very
similar to the structures reported for dasatinib
in complex with the WT Abl kinase domain
64
and  of  MK-0457  in  complex  with  the  Abl
mutant  H396P.
25 The  mutation  of  the  threo-
nine to the more bulky isoleucine does not
seem to cause any widespread conformational
changes but creates a steric hindrance that
would interfere with the binding of inhibitors,
such  as  imatinib,  nilotinib,  and  dasatinib,
which make use of the hydrophobic pocket.
The binding mode of PHA-739358 is very sim-
ilar  to  that  reported  for  the  complex  of  the
same compound with aurora A (Figure 5B and
D), although the conformation of the proteins
around the ATP-binding site shows some dif-
ferences because in the aurora A structure the
DFG motif is more similar to the ‘‘out’’ confor-
mation. However, all of the essential contacts
between  PHA-739358  and  Abl  T315I  involve
highly  conserved  elements.  The  molecule
makes three hydrogen bonds with the protein
Figure 5. Structure of Abl-T315I-PHA 739358 complex. (A) Ribbon representation of the
structure  of  T315I  Abl  mutant  with  PHA-739358.  The  mutated  gatekeeper  residue
Ile315 and the activation loop with the phosphorylated residue Tyr393 are highlighted
in green. (B) Close-up view of the binding site of PHA-739358 showing the final 2 Fo-
Fc electron density map, contoured at 1 j, associated with the ligand. (C) Chemical for-
mula of PHA 739358. (D) Comparison of PHA-739358 complexes with the aurora A
structure. Details of the binding of PHA-739358 to Abl (green carbon atoms) and to
aurora A (yellow carbon atoms) showing the residues of the hinge region and of the DFG
motif  of  both  proteins.  [Reprinted  and  adapted  with  permission  of  AACR  from:
Modugno M, et al. Crystal structure of the T315I Abl mutant in complex with the auro-
ra kinases inhibitor PHA-739358. Cancer Res 2007 Sep 1;67(17):7987-90].
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I315
Y395
Y320
F317
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F382
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E266
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Leu 210
Aurora: VX-680 (model) T315I-Bcr-Abl: VX-680 (model)
Figure 4. Binding mode of VX-680 to aurora A and T315I-Bcr-Abl. Both leucine
210 and
isoleucine
315 side chains can be accommodated between the two arms of the “Y” of VX-
680. [Reprinted and adapted with permission of AACR from: Young MA, et al. Structure
of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora
kinase inhibitor VX-680. Cancer Res 2006 Jan 15;66(2):1007-14].
Aurora: VX-680 (model)
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backbone of the hinge region: the two nitro-
gen atoms of the pyrrolopyrazole core interact
with the carbonyl oxygen of Glu316 and with
the amide nitrogen of Met318, whereas the
nitrogen of the amide group hydrogen bonds
to the carbonyl oxygen of Met318. In addition,
the  side  chain  nitrogen  of  the  conserved
Lys271 is within hydrogen bonding distance
of the oxygen of the carbonyl group and the
oxygen of the methoxy group. As in the auro-
ra structure, the benzyl group packs against
Leu370 (Leu263 in aurora), whereas the N-
methyl-piperazine points toward the solvent
accessible  area  of  the  kinase  pocket.  The
gatekeeper residue in the aurora kinases is
Leu210, a large and hydrophobic residue very
similar to isoleucine, and we have observed
that  PHA-739358  binds  in  the  ATP-binding
pocket  of  aurora  A  without  any  steric  hin-
drance with the gatekeeper residue. Indeed,
the co-crystal structure reported here reveals
that the compound is bound to the Abl T315I
kinase domain in a way that accommodates
the substitution of isoleucine for threonine.
Figure 6 shows the structure of the Abl T315I
complex  with  PHA-739358  superimposed  on
those  of  the  Abl  WT  with  imatinib  and  Abl
H396P with MK-0457. In the T315I mutant,
the isoleucine side chain causes a steric clash
with imatinib and the hydrogen bond between
imatinib and the side chain oxygen of threo-
nine is lost (Figure 6A and B). On the con-
trary, both PHA-739358 and MK-0457 bind in
such a way to avoid the gatekeeper residue
(Figure 6C) and this provides an explanation
for the ability of both compounds to accommo-
date  the  isoleucine  substitution.  Further  -
more,  the  pyrrolopyrazole  scaffold  of  PHA-
739358 is situated within van der Waals dis-
tance of the side chain of Ile315 mimicking
the  interaction  between  the  inhibitor  and
Leu210 in aurora A. It is possible that this
favorable  hydrophobic  packing  interaction
may explain why PHA-739358 is more active
against the mutant than the WT protein. PHA-
739358 could represent a valuable novel agent
to target the T315I Bcr-Abl mutation, and pre-
clinical and clinical data are coming through
to support this concept. 
Conclusions
The T315I is responsible for approximately
15% of the cases of relapse in CML and Ph
+
ALL patients on imatinib therapy. The clinical
relevance of this mutant is likely to increase
considerably as to date it seems to represent
the main mechanism of resistance to dasa-
tinib  and  nilotinib,  the  second-generation
inhibitors already being developed clinically.
Structural analyses indicate that the substitu-
tion of threonine with isoleucine at residue
315  eliminates  a  crucial  hydrogen-bonding
interaction  and  introduces  a  steric  clash
which abrogates binding and effective inhibi-
tion of Bcr-Abl by imatinib as well as by sever-
al novel inhibitors. A possible approach to the
development  of  second-line  strategies  over-
coming resistance induced by the T315I muta-
tion is to design inhibitors binding regions of
Bcr-Abl other than the ATP binding pocket. An
intriguing alternative is to explore the possi-
bility  of  whether  molecules  that  have  been
developed  as  inhibitors  for  other  protein
kinases  and  are  already  undergoing  clinical
trials might include the T315I-Bcr-Abl mutant
among  their  off-targets.  Although  off-target
activity may lead to undesirable side effects, it
has to be recognized that focusing on com-
pounds that are already being tested in clinical
practice may speed up the development of suc-
cessful therapeutic strategies. Recent studies
have shown that MK-0457 (VX-680) and PHA-
739358,  two  small-molecule  aurora  kinase
inhibitors, have in vitro activity against the
T315I-Bcr-Abl.  Moreover,  preliminary  data
showed promising clinical efficacy in patients
affected  by  Philadelphia  positive  leukemias,
relapsing or resistant to first and second gen-
eration TK inhibitors. Such a remarkable effi-
cacy  raises  the  question  of  whether  aurora
kinases may also harbor some pathogenetic
significance in CML and/or Ph
+ ALL or may be
selectively  deregulated  by  the  T315I-Bcr-Abl,
and whether auroras may be a suitable sec-
ondary target for inhibition.
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